 |
|
|
| |
Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy
|
| |
| |
European Association for the Study of the Liver; 05-08 June 2024; Milan, Italy
Fabien Zoulim1, Vladimir Chulanov2, Pietro Lampertico3,4, Heiner Wedemeyer5, Adrian Streinu-Cercel6,7, Victor Pantea8, Stefan Lazar9, George Sebastian Gherlan7,10, Pavel Bogomolov11, Tatyana Stepanova12, Viacheslav Morozov13,
Vladimir Syutkin14, Olga Sagalova15, Dmitry Manuilov16, Renee-Claude Mercier16, Lei Ye16, Grace M Chee16, Ben L Da16, Audrey H Lau16, Anu Osinusi16, Marc Bourlière17, Vlad Ratziu18, Stanilas Pol19, Marie-Noëlle Hilleret20, Tarik Asselah21
|
| |
|
|
|
|
|
